JP2003528144A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528144A5 JP2003528144A5 JP2001570263A JP2001570263A JP2003528144A5 JP 2003528144 A5 JP2003528144 A5 JP 2003528144A5 JP 2001570263 A JP2001570263 A JP 2001570263A JP 2001570263 A JP2001570263 A JP 2001570263A JP 2003528144 A5 JP2003528144 A5 JP 2003528144A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- substance
- carboxy
- primary headache
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2000/001138 WO2001072302A1 (en) | 2000-03-24 | 2000-03-24 | Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528144A JP2003528144A (ja) | 2003-09-24 |
| JP2003528144A5 true JP2003528144A5 (https=) | 2007-05-10 |
Family
ID=9883925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001570263A Pending JP2003528144A (ja) | 2000-03-24 | 2000-03-24 | 頭痛治療のためのプロスタノイドep4受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1267867B1 (https=) |
| JP (1) | JP2003528144A (https=) |
| AT (1) | ATE395058T1 (https=) |
| AU (2) | AU3445100A (https=) |
| CA (1) | CA2402099C (https=) |
| DE (1) | DE60038902D1 (https=) |
| DK (1) | DK1267867T3 (https=) |
| WO (1) | WO2001072302A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050059742A1 (en) * | 2001-10-31 | 2005-03-17 | Jabbour Henry Nicolas | Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorphagia |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| JP5301469B2 (ja) * | 2007-02-26 | 2013-09-25 | メルク カナダ インコーポレイテッド | Ep4受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体 |
| EP2846793A1 (en) | 2012-05-09 | 2015-03-18 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
| CN110621667A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 嘧啶衍生物 |
| EP3625224B1 (en) | 2017-05-18 | 2021-08-04 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| PL3625228T3 (pl) | 2017-05-18 | 2021-12-20 | Idorsia Pharmaceuticals Ltd | Pochodne pirymidyny jako modulatory receptora pge2 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2179399A1 (en) * | 1993-12-20 | 1995-06-29 | Kiyoshi Taniguchi | 4,5-diaryloxazole derivatives |
| AUPO713297A0 (en) * | 1997-06-02 | 1997-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compound |
| GB9720270D0 (en) * | 1997-09-25 | 1997-11-26 | Pharmagene Lab Limited | Medicaments for the treatment of migraine |
| DE60012751T2 (de) * | 1999-08-10 | 2005-01-20 | Glaxo Group Ltd., Greenford | Verwendung von EP 4 Rezeptorliganden zur Behandlung von neuropathischem Schmerz |
-
2000
- 2000-03-24 AU AU3445100A patent/AU3445100A/xx active Pending
- 2000-03-24 DK DK00912807T patent/DK1267867T3/da active
- 2000-03-24 WO PCT/GB2000/001138 patent/WO2001072302A1/en not_active Ceased
- 2000-03-24 AU AU2000234451A patent/AU2000234451B2/en not_active Ceased
- 2000-03-24 EP EP00912807A patent/EP1267867B1/en not_active Expired - Lifetime
- 2000-03-24 JP JP2001570263A patent/JP2003528144A/ja active Pending
- 2000-03-24 AT AT00912807T patent/ATE395058T1/de not_active IP Right Cessation
- 2000-03-24 DE DE60038902T patent/DE60038902D1/de not_active Expired - Lifetime
- 2000-03-24 CA CA2402099A patent/CA2402099C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU760735B2 (en) | A method for treating inflammatory diseases by administering a thrombin inhibitor | |
| TWI432417B (zh) | 充當生長激素促分泌素受體之格琳(Ghrelin)類似物配體的新穎三唑衍生物 | |
| TW202327569A (zh) | 包含tead抑制劑的藥物組合及其用於癌症治療之用途 | |
| SK13952002A3 (sk) | Farmaceutická kompozícia na liečenie akútnej, chronickej a/alebo neuropatickej bolesti a migrén | |
| CA2813648C (en) | Combinations of serotonin receptor agonists for treatment of movement disorders | |
| JP2004511466A5 (https=) | ||
| JP2009536220A5 (https=) | ||
| JP2002533407A (ja) | 新形成の治療におけるマトリクスメタロプロテイナーゼ阻害剤とインテグリン拮抗剤の使用 | |
| JP2006503850A5 (https=) | ||
| JP2012255039A (ja) | ニコチン性アセチルコリンα7受容体アゴニストの組合せ剤 | |
| JP2003528144A5 (https=) | ||
| JP2003519228A5 (https=) | ||
| IL179599A0 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
| JP2012522805A5 (https=) | ||
| CA2402099A1 (en) | Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment | |
| JP2000198734A (ja) | 胃運動性減弱および関連疾患の治療のための運動性増強薬 | |
| JP2003510355A (ja) | 精神障害におけるnk1レセプターアンタゴニストとgaba類縁体との共働的組合せ体の使用 | |
| JP2002121153A (ja) | 抑うつ及び不安のための併合療法 | |
| JPH06500099A (ja) | Cns疾病の処置におけるヘテロ環状アミノ―アルコール化合物の使用 | |
| JP2007516292A5 (https=) | ||
| JP2004533986A5 (https=) | ||
| EA015483B1 (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ | |
| KR20210062023A (ko) | Crac 억제제 및 코르티코스테로이드를 포함하는 조성물 및 그의 사용 방법 | |
| JP2008501632A5 (https=) | ||
| JP2016540737A (ja) | 注意障害用および認知障害用ならびに神経変性障害に関連する認知症用の治療剤 |